PC
LOXO

Paulson & Co’s Loxo Oncology, Inc LOXO Stock Holding History

Paulson & Co’s Portfolio LOXO Stock Details LOXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-22,800
Closed -$2.1M – 61
2017
Q3 		$2.1M Sell
22,800
-664,093
-97% -$51.6M 0.04% 52
2017
Q2 		$55.1M Sell
686,893
-125,607
-15% -$6.96M 0.74% 30
2017
Q1 		$34.2M Sell
812,500
-16,141
-2% -$665K 0.45% 35
2016
Q4 		$26.6M Buy
828,641
+91,700
+12% +$2.35M 0.34% 43
2016
Q3 		$19.3M Buy
736,941
+486,600
+194% +$12.7M 0.21% 47
2016
Q2 		$5.8M Buy
250,341
+25,000
+11% +$622K 0.06% 63
2016
Q1 		$6.16M Buy
225,341
+143,162
+174% +$3M 0.05% 65
2015
Q4 		$2.34M Buy
+82,179
New +$2.21M 0.01% 67

Other funds holding LOXO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Paulson & Co's LOXO Position: Q4 2017 in Review

Paulson & Co sold out of Loxo Oncology, Inc (LOXO) in Q4 2017, closing a stake of 22,800 shares — an estimated $2.1M sold.

Paulson & Co first reported a position in LOXO in Q4 2015 and held it in 8 quarters. The position peaked at $55.1M in Q2 2017. 141 funds tracked by Wall St. Rank hold LOXO as of Q4 2017.

  • Paulson & Co reported no remaining Loxo Oncology, Inc position as of Q4 2017 after selling out during the quarter.
  • Paulson & Co sold 22,800 Loxo Oncology, Inc shares in Q4 2017, an estimated $2.1M.
  • Paulson & Co first reported a position in Loxo Oncology, Inc in Q4 2015 and held it in 8 quarters.
  • Paulson & Co's Loxo Oncology, Inc position peaked at $55.1M in Q2 2017.
  • 141 funds tracked by Wall St. Rank held Loxo Oncology, Inc as of Q4 2017.

Based on Paulson & Co's 13F filing for Q4 2017, filed 14 Feb 2018.